SleepCited

Melatonin in sleep disorders.

J J Poza, M Pujol, J J Ortega-Albás, O Romero, en representación del Grupo de estudio de insomnio de la Sociedad Española de Sueño (SES)
Review Neurologia 2022 78 件の引用

研究デザイン

研究タイプ
Review
対象集団
Patients with insomnia and sleep disorders, particularly older adults with age-related melatonin decrease
介入
Melatonin in sleep disorders.
比較対照
Placebo or no treatment
主要アウトカム
Clinical usefulness of melatonin for insomnia and sleep disorders
効果の方向
Neutral
バイアスリスク
Unclear

抄録

Melatonin is the main hormone involved in the control of the sleep-wake cycle. It is easily synthesisable and can be administered orally, which has led to interest in its use as a treatment for insomnia. Moreover, as production of the hormone decreases with age, in inverse correlation with the frequency of poor sleep quality, it has been suggested that melatonin deficit is at least partly responsible for sleep disorders. Treating this age-related deficit would therefore appear to be a natural way of restoring sleep quality, which is lost as patients age. However, despite the undeniable theoretical appeal of this approach to insomnia, little scientific evidence is available that supports any benefit of this substitutive therapy. Furthermore, the most suitable dose ranges and pharmaceutical preparations for melatonin administration are yet to be clearly defined. This review addresses the physiology of melatonin, the different pharmaceutical preparations, and data on its clinical usefulness.

要約

Despite the undeniable theoretical appeal of this approach to insomnia, little scientific evidence is available that supports any benefit of this substitutive therapy and the most suitable dose ranges and pharmaceutical preparations for melatonin administration are yet to be clearly defined.

エビデンスレビューでの引用